NCT07344688

Brief Summary

This clinical study aims to determine the effects of consuming white tea infusion (Camellia sinensis) on healthy subjects over a period of 14 days. The main questions it aims to answer are:

  1. 1.Determine the effect of white tea consumption on the anthropometry of healthy subjects.
  2. 2.Determine the effect of white tea consumption on the biochemical parameters of healthy subjects.
  3. 3.Determine the effect of white tea consumption on hematology parameters that are related to anemia case in healthy subjects.
  4. 4.Determine the effect of white tea consumption on the activity of first-line antioxidant enzymes in healthy subjects
  5. 5.Follow the washout stage for 7 days
  6. 6.Drink white tea infusion every day for 14 days.
  7. 7.Follow up to monitor adverse effects after consuming white tea; this stage will be conducted for 7 days.
  8. 8.Report all food and beverages consumed by respondents during the study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 22, 2025

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

September 12, 2025

Completed
15 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 27, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 15, 2026

Completed
Last Updated

April 17, 2026

Status Verified

April 1, 2026

Enrollment Period

1 month

First QC Date

September 12, 2025

Last Update Submit

April 15, 2026

Conditions

Outcome Measures

Primary Outcomes (7)

  • Antioxidant Enzymes Analysis

    Comparing the antioxidant activity values of enzymes including superoxide dismutase, catalase, and glutathione peroxidase in pre and post white tea treatment (day 0 and day 15). The increased activity of antioxidant enzymes signifies an enhancement in the body's capability to combat free radicals. The analysis will be conducted using a reagent kit to obtain the antioxidant enzyme activity values in the respondents' serum. All antioxidant enzyme parameter values are expressed in U/mL.

    14 days

  • Liver Function Analysis

    The effect of the product on liver function will be analysed based on SGOT and SGPT values. A drastic increase compared to the pre-intervention level indicates potential toxicity. Both parameters will be expressed in units of ukat/L.

    14 days

  • estimated Glomerular filtration rate

    A drastic decrease in eGFR indicates the potential toxicity of white tea beverages. eGFR results of respondents will be expressed in mL/min/1.73m2

    14 days

  • Lipid profile measurement

    The effect of product administration on lipid profile was assessed by measuring total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) parameters. Product effectiveness was determined based on the stability or decrease in total cholesterol, triglycerides, and LDL values, as well as an increase in HDL values post-treatment compared to pre-treatment values. Total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) will be expressed in mmol/L

    14 days

  • Fasting blood glucose measurement

    Fasting blood glucose will be expressed in mmol/L

    14 days

  • Serum creatinine Analysis

    An elevated serum creatinine level is an indication of potential toxicity associated with white tea consumption. Serum creatinine level will be expressed in umol/L

    14 days

  • Blood Urea Nitrogen Analysis

    An elevated blood urea nitrogen level is an indication of potential toxicity associated with white tea consumption. The parameter will be written in units of mmol/L

    14 days

Secondary Outcomes (12)

  • Body Weight Measurement

    14 days

  • Body Height Measurement

    14 days

  • Body Mass Index

    14 days

  • Waist Circumference Measurement

    14 days

  • Blood Pressure Measurement

    14 days

  • +7 more secondary outcomes

Study Arms (1)

White tea intervention

EXPERIMENTAL

Nineteen respondents will be given 200 mL of white tea (4 grams of white tea sample in 200 mL of water at a temperature of 95-98°C) for 14 days after a 7-day washout period. In the final stage, all respondents will undergo an observation phase. In the final stage, all respondents are required to submit updates on their physical condition. If they experience discomfort such as nausea, dizziness, or general unease, the respondents will be examined by the research physician. In our study, no control group was used. To demonstrate the effect of white tea on the respondents' health condition, we compared the results before and after the treatment.

Other: White tea intervention

Interventions

1. White tea infusion was prepared by brewing 4 grams of white tea in 200 mL of hot water. 2. Healthy respondents were asked to consume the white tea infusion for 14 days. 3. The focus of this study was to observe the effect of white tea infusion on antioxidant enzyme activity and its relationship with anthropometric, biochemical, and haematological parameters.

White tea intervention

Eligibility Criteria

Age20 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • The participants are the community around Padjadjaran University with an age range of 20 - 35 years old. Female respondents were unmarried.
  • The participants are non-smoker.
  • The participants should have no history of anemia, chronic disease, hepatic and renal dysfunction.
  • The participants are willing to follow the research process until its finish by signing an informed consent form.

You may not qualify if:

  • The participants who are undergoing drug therapy and taking vitamin supplements.
  • The participants who failed due to illness or are unable to continue the examination to the end.
  • Respondents with pre-treatment biochemical results not within the normal range

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Pharmacy, Padjadjaran University

Sumedang, West Java, 45363, Indonesia

Location

Study Officials

  • Gofarana Wilar, Ph.D.

    Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 12, 2025

First Posted

January 15, 2026

Study Start

August 22, 2025

Primary Completion

September 27, 2025

Study Completion

December 30, 2025

Last Updated

April 17, 2026

Record last verified: 2026-04

Locations